Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Keryx Biopharmaceuticals, Inc. Snapshot 6
Keryx Biopharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Keryx Biopharmaceuticals, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Keryx Biopharmaceuticals, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Keryx Biopharmaceuticals, Inc. – Pipeline Products Glance 12
Keryx Biopharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Keryx Biopharmaceuticals, Inc.–Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Keryx Biopharmaceuticals, Inc. – Drug Profiles 15
KRX-0701 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
KRX-123 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
KRX-252 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
KRX-341 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
KRX-613 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
KRX-683 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
KW-2401 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Keryx Biopharmaceuticals, Inc. – Pipeline Analysis 22
Keryx Biopharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 22
Keryx Biopharmaceuticals, Inc. - Pipeline Products By Target 23
Keryx Biopharmaceuticals, Inc. – Pipeline Products by Route of Administration 24
Keryx Biopharmaceuticals, Inc. – Pipeline Products by Molecule Type 25
Keryx Biopharmaceuticals, Inc. – Recent Pipeline Updates 26
Keryx Biopharmaceuticals, Inc. - Dormant Projects 30
Keryx Biopharmaceuticals, Inc. – Company Statement 32
Keryx Biopharmaceuticals, Inc. – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Nov 30, 2010: Keryx's Phase III Study Of Hyperphosphatemia Drug Meets Primary And Key Secondary Endpoints 36
Jun 29, 2010: Keryx To Present Data On KRX-0401 At Upcoming 12th World Congress On Gastrointestinal Cancer 37
Dec 17, 2002: Keryx Biopharmaceuticals Provides Update On KRX-123, Its Drug Candidate For Hormone Resistant Prostate Cancer 37
Jan 14, 2002: Access Oncology Pays Upto $33 million To Gem Pharmaceuticals For Two Products Including GPX-100 37
Jan 10, 2002: ACCESS Oncology, Inc. And Gem Pharmaceuticals, Inc. Signs Product Partnership For Non-Cardiotoxic Anthracyclines Products Including GPX-100 38
Financial Deals Landscape 39
Keryx Biopharmaceuticals, Inc., Deals Summary 39
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 41
Asset Transactions 41
Keryx Biopharmaceuticals Acquires Accumin From AusAm Biotechnologies 41
Partnerships 43
AEterna Zentaris Enters Into Development Agreement With Keryx Biopharmaceuticals 43
Licensing Agreements 45
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Japan Tobacco And Torii Pharmaceutical 45
KYOWA HAKKO KOGYO Enters Into Licensing Agreement With Keryx Biopharmaceuticals 47
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Panion & BF Biotech 49
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Krenitsky Pharmaceuticals 50
AEterna Zentaris Enters Into Licensing Agreement With Keryx Biopharmaceuticals 51
Equity Offering 52
Keryx Biopharmaceuticals Completes Underwritten Public Offering Of $33 Million 52
Keryx Biopharmaceuticals Completes Registered Direct Offering Of $20 Million 54
Keryx Biopharmaceuticals Completes Private Placement Of $82.8 Million 56
Keryx Biopharmaceuticals Completes Public Offering Of $81.2 Million 58
Keryx Biopharmaceuticals Completes Private Placement Of $0.32 Million 60
Acquisition 62
Keryx Biopharmaceuticals Acquires ACCESS Oncology 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 64
Contact Us 64
Disclaimer 64
List of Tables
Keryx Biopharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 9
Keryx Biopharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 10
Keryx Biopharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011 11
Keryx Biopharmaceuticals, Inc. - Phase II, H2 2011 12
Keryx Biopharmaceuticals, Inc. - Phase I, H2 2011 13
Keryx Biopharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011 22
Keryx Biopharmaceuticals, Inc. - Pipeline By Target, H2 2011 23
Keryx Biopharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011 24
Keryx Biopharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011 25
Keryx Biopharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011 26
Keryx Biopharmaceuticals, Inc. - Dormant Developmental Projects, 2010 30
Keryx Biopharmaceuticals, Inc., Subsidiaries 35
Keryx Biopharmaceuticals, Inc., Deals Summary 39
Keryx Biopharmaceuticals Acquires Accumin From AusAm Biotechnologies 41
AEterna Zentaris Enters Into Development Agreement With Keryx Biopharmaceuticals 43
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Japan Tobacco And Torii Pharmaceutical 45
KYOWA HAKKO KOGYO Enters Into Licensing Agreement With Keryx Biopharmaceuticals 47
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Panion & BF Biotech 49
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Krenitsky Pharmaceuticals 50
AEterna Zentaris Enters Into Licensing Agreement With Keryx Biopharmaceuticals 51
Keryx Biopharmaceuticals Completes Underwritten Public Offering Of $33 Million 52
Keryx Biopharmaceuticals Completes Registered Direct Offering Of $20 Million 54
Keryx Biopharmaceuticals Completes Private Placement Of $82.8 Million 56
Keryx Biopharmaceuticals Completes Public Offering Of $81.2 Million 58
Keryx Biopharmaceuticals Completes Private Placement Of $0.32 Million 60
Keryx Biopharmaceuticals Acquires ACCESS Oncology 62
List of Figures
Keryx Biopharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 8
Keryx Biopharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 10
Keryx Biopharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011 11
Keryx Biopharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011 22
Keryx Biopharmaceuticals, Inc. - Pipeline By Target, H2 2011 23
Keryx Biopharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011 25